Healthcare

Zoetis is a global leader in animal health, with a strong shift toward higher-margin pet care, durable cash generation, and standout profitability. The key debate is whether newer therapies and diagnostics can revive growth after a sharp valuation reset.

WuXi Biologics helps drug companies develop and manufacture biologic medicines from early research to commercial supply. Strong margins, cash generation, and global scale stand out, while the main debate centers on how much geopolitical pressure can limit its reach.

West Pharmaceutical Services makes critical packaging and delivery components for injectable drugs. Recent growth has improved, cash generation remains solid, and its niche in biologics and self-injection supports a strong long-term business profile.

Waters makes specialized laboratory instruments, consumables, and services used in drug development and testing. Its appeal comes from recurring revenue, strong positions in chromatography, and expansion into biologics and clinical workflows.

Viatris sells a broad global portfolio of generic and established medicines while building newer areas like biosimilars and complex injectables. Improving revenue trends and strong cash flow make the company worth a closer look in a still-challenging operating environment.

Veeva Systems provides cloud software for life sciences, covering commercial, clinical, regulatory, quality, and data workflows. Strong recurring revenue, rising cash flow, high margins, and a near-debt-free balance sheet make its long-term business profile especially compelling.

United Therapeutics is a rare-disease biotech built around a highly profitable pulmonary hypertension franchise. Strong cash flow, minimal leverage, and growing transplant-related ambitions make it an especially interesting company to examine over the long term.